Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

@article{Liegl2008HeterogeneityOK,
  title={Heterogeneity of kinase inhibitor resistance mechanisms in GIST.},
  author={Bernadette Liegl and Ilana Kepten and Claudia Le and Mei-Jun Zhu and George D. Demetri and Michael C Heinrich and Christopher D. M. Fletcher and Christopher L. Corless and Jonathan Alfred Fletcher},
  journal={The Journal of pathology},
  year={2008},
  volume={216 1},
  pages={
          64-74
        }
}
Most GIST patients develop clinical resistance to KIT/PDGFRA tyrosine kinase inhibitors (TKI). However, it is unclear whether clinical resistance results from single or multiple molecular mechanisms in each patient. KIT and PDGFRA mutations were evaluated in 53 GIST metastases obtained from 14 patients who underwent surgical debulking after progression on imatinib or sunitinib. To interrogate possible resistance mechanisms across a broad biological spectrum of GISTs, inter- and intra-lesional… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 193 CITATIONS, ESTIMATED 42% COVERAGE

Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight.

  • Journal of biomolecular structure & dynamics
  • 2014
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 5 EXCERPTS
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 14 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
VIEW 4 EXCERPTS

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 1 EXCERPT

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 1 EXCERPT